PTPRC and adenocarcinoma: In a study by Suad M. Abdirahman et al., 18.2% (4/22) of CRC PDX models formed lymphocytic tumors, with an additional 18.2% exhibiting adenocarcinoma and/or lymphoma,30 marked by CD45+ lymphocytes and atypical large lymphoid cells.